MX364587B - Formulaciones reconstituidas de hdl. - Google Patents

Formulaciones reconstituidas de hdl.

Info

Publication number
MX364587B
MX364587B MX2015004546A MX2015004546A MX364587B MX 364587 B MX364587 B MX 364587B MX 2015004546 A MX2015004546 A MX 2015004546A MX 2015004546 A MX2015004546 A MX 2015004546A MX 364587 B MX364587 B MX 364587B
Authority
MX
Mexico
Prior art keywords
reconstituted hdl
formulations
hdl formulation
formulation
reconstituted
Prior art date
Application number
MX2015004546A
Other languages
English (en)
Other versions
MX2015004546A (es
Inventor
Vucica Yvonne
Lee Warren Gary
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of MX2015004546A publication Critical patent/MX2015004546A/es
Publication of MX364587B publication Critical patent/MX364587B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formulaciones reconstituidas de lipoproteína de alta densidad (HDL), que comprenden una apolipoproteína, un lípido y un estabilizante de liofilización. Dichas formulaciones tienen toxicidad renal reducida y buena estabilidad a largo plazo, especialmente en forma liofilizada.
MX2015004546A 2012-11-02 2013-10-31 Formulaciones reconstituidas de hdl. MX364587B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261721771P 2012-11-02 2012-11-02
EP13153903 2013-02-04
US13/803,863 US9125943B2 (en) 2012-11-02 2013-03-14 Reconstituted HDL formulation
AU2013205684A AU2013205684B2 (en) 2012-11-02 2013-04-10 Reconstituted hdl formulation
PCT/AU2013/001260 WO2014066943A1 (en) 2012-11-02 2013-10-31 Reconstituted hdl formulation

Publications (2)

Publication Number Publication Date
MX2015004546A MX2015004546A (es) 2015-07-14
MX364587B true MX364587B (es) 2019-05-02

Family

ID=47665977

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004546A MX364587B (es) 2012-11-02 2013-10-31 Formulaciones reconstituidas de hdl.

Country Status (16)

Country Link
US (5) US9125943B2 (es)
EP (2) EP3502131A1 (es)
JP (1) JP6340372B2 (es)
KR (1) KR102263810B1 (es)
CN (2) CN104755096B (es)
AU (1) AU2013205684B2 (es)
BR (1) BR112015009748B1 (es)
CA (1) CA2889785C (es)
HK (1) HK1212599A1 (es)
IL (1) IL238504B (es)
MX (1) MX364587B (es)
NZ (1) NZ631131A (es)
PL (1) PL2916857T3 (es)
RU (1) RU2669568C2 (es)
SG (1) SG11201503083UA (es)
WO (1) WO2014066943A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012000048A1 (en) 2010-06-30 2012-01-05 Csl Limited A reconstituted high density lipoprotein formulation and production method thereof
US9125943B2 (en) * 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
ES2940304T3 (es) 2013-06-05 2023-05-05 Csl Ltd Proceso para preparar apolipoproteína A-I (Apo A-I)
NZ631126A (en) 2013-08-08 2018-06-29 Csl Ltd Contaminant removal method
EP3490579A1 (en) 2016-07-27 2019-06-05 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
KR20240044543A (ko) 2016-11-10 2024-04-04 시에스엘 리미티드 심근경색의 재구성된 고밀도 지질단백질 치료
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
IL161110A0 (en) 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
WO2003097696A1 (en) 2002-05-17 2003-11-27 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
JP2006507223A (ja) 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
KR100992488B1 (ko) 2006-12-29 2010-11-05 주식회사 녹십자 ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법
WO2009025754A2 (en) 2007-08-17 2009-02-26 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
WO2012000048A1 (en) 2010-06-30 2012-01-05 Csl Limited A reconstituted high density lipoprotein formulation and production method thereof
CA2826158A1 (en) 2011-02-07 2012-08-16 Rose ACKERMANN Lipoprotein complexes and manufacturing and uses thereof
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation

Also Published As

Publication number Publication date
US11464828B2 (en) 2022-10-11
BR112015009748A2 (pt) 2017-07-11
JP2015535263A (ja) 2015-12-10
CN104755096A (zh) 2015-07-01
AU2013205684A1 (en) 2014-05-22
EP2916857B1 (en) 2019-01-16
JP6340372B2 (ja) 2018-06-06
US10603355B2 (en) 2020-03-31
SG11201503083UA (en) 2015-05-28
US20190015476A1 (en) 2019-01-17
EP2916857A4 (en) 2016-05-25
RU2015120808A (ru) 2016-12-20
CN108057023B (zh) 2022-02-08
CA2889785A1 (en) 2014-05-08
IL238504B (en) 2018-02-28
AU2013205684B2 (en) 2015-08-20
WO2014066943A1 (en) 2014-05-08
PL2916857T3 (pl) 2019-06-28
US20150306176A1 (en) 2015-10-29
EP3502131A1 (en) 2019-06-26
US20140221272A1 (en) 2014-08-07
EP2916857A1 (en) 2015-09-16
BR112015009748B1 (pt) 2021-04-27
CN108057023A (zh) 2018-05-22
KR102263810B1 (ko) 2021-06-15
IL238504A0 (en) 2015-06-30
MX2015004546A (es) 2015-07-14
RU2669568C2 (ru) 2018-10-12
KR20150079947A (ko) 2015-07-08
US20200397859A1 (en) 2020-12-24
CN104755096B (zh) 2017-10-13
HK1212599A1 (zh) 2016-06-17
US9925236B2 (en) 2018-03-27
US9125943B2 (en) 2015-09-08
US11957731B2 (en) 2024-04-16
CA2889785C (en) 2022-07-19
NZ631131A (en) 2015-12-24
US20230142696A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
MX364587B (es) Formulaciones reconstituidas de hdl.
JOP20180103A1 (ar) مركب صيدلاني
MX354867B (es) Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
IN2014DN07322A (es)
IL234550A (en) Systems for carrying fatty acids and preparations for targeted delivery
WO2013177419A3 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
EP2547209A4 (en) FUNGICIDAL COMPOSITIONS COMPRISING A PHOSPHATE SOLUBILIZING MICROORGANISM AND A FUNGICIDE ACTIVE COMPOUND
MX337437B (es) Composiciones topicas para conservador o restaurar la integridad de la mucosa.
IN2015DN03322A (es)
WO2014057362A3 (en) Omega -3 compositions
ECSP13013018A (es) Composiciones nutricionales fortificadas a base de leche
CY1124808T1 (el) Σκευασματα για τη σταθεροποιηση της υγρασιας σε τροφιμα κρεατος
AU337887S (en) Allsaw
WO2015058173A8 (en) Stable solid units and methods of making the same
PH12015502014A1 (en) Racecadotril lipid compositions
PH12014502858A1 (en) Racecadotril lipid compositions
WO2013111012A3 (en) Methods and compositions for therapeutic agents
CY1119064T1 (el) Ινωδολυτικες συνθεσεις οι οποιες περιεχουν βρωμελαϊνη και ναττοκιναση για την προληψη και αγωγη φλεβοθρομβωτικων καταστασεων
BR112015013178A2 (pt) composição e composição para uso para proteger um animal não humano contra a coccidiose
SG10201803999UA (en) Recombinant factor viii formulations
MX2019002024A (es) Antigenos de pertussis acelulares no entrelazados para uso en vacunas de combinacion.
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
IN2014DN07525A (es)
IN2014MN01382A (es)

Legal Events

Date Code Title Description
FG Grant or registration